Snowbird Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2009


Here are the related meetings in 2018:
Cancer Immunotherapy: Combinations (C5)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Mobilizing Cellular Immunity for Cancer Therapy (A3)


Organizer(s) Philip D. Greenberg, James P. Allison and Cornelia L. Trimble
January 11—16, 2009
Snowbird Resort • Snowbird, Utah USA
Abstract Deadline: Sep 16, 2008
Late Abstract Deadline: Oct 14, 2008
Scholarship Deadline: Sep 16, 2008
Early Registration Deadline: Nov 11, 2008

Sponsored by Pfizer Global Research & Development

Summary of Meeting:
Studies demonstrating the role of the immune system in the development and/or prevention of cancer, and elucidating the obstacles limiting an effective immune response to progressing tumors, have suggested strategies for manipulating the immune system to promote eradication of established tumors. This meeting will bring together investigators probing innate and adaptive immune systems, as well as regulatory pathways, to provide a context for developing effective tumor immunotherapies. The major objectives will be as follows: (1) explore the dual roles that components of the immune system can play early in developing malignancies, leading to protection or tumor promotion; (2) examine the mechanisms by which immune responses can be subverted by the malignant process; (3) describe the rationale for and potential benefit of immunotherapeutic strategies currently being explored for modulating adaptive immunity to achieve therapeutic anti-tumor responses; and (4) discuss the rationale for concurrently employing multiple immunosupportive modalities to enhance immunotherapeutic strategies.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, JANUARY 11

15:00—19:30
Registration

Ballroom Lobby
18:30—19:30
Refreshments

Ballroom Lobby
19:30—21:30
Keynote Session
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
Irving L. Weissman, Stanford University, USA
Normal and Neoplastic Stem Cell

Stephen S. Hall, , USA
"More Commotion in the Blood:" A Science Writer's View from the Sidelines


MONDAY, JANUARY 12

07:00—08:00
Breakfast

Golden Cliff / Eagles
08:00—11:00
Tumor Surveillance and Microenvironment
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Robert D. Schreiber, Washington University School of Medicine, USA
The Outgrowth of Cancer – A Problem of Disequilibrium

David H. Raulet, University of California, Berkeley, USA
NK Cell Recognition of Ligands on Transformed Cells

Anna Wasiuk, Oregon Health & Science University, USA
Short Talk: Acquired Immune Privilege within the Tumor Microenvironment: Mast Cells Suppress the Development of Protective Anti-Tumor Immunity while Enhancing Tumor-Induced Angiogenesis

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Dissecting and Manipulating the Balance between Procarcinogenic and Anti-Carcinogenic Immunity

Jeffrey W. Pollard, Queen's Medical Research Institute, UK
Tumor Educated Macrophages Stimulate Malignant Progression and Enhance Metastasis

09:20—09:40
Coffee Break

Ballroom Lobby
11:00
On Own for Lunch

11:00—13:00
Poster Setup

Superior / Superior Lobby / Wasatch / Maybird
13:00—22:00
Poster Viewing

Superior / Superior Lobby / Wasatch / Maybird
14:30—16:30
Workshop 1: Events in the Microenvironment

Ballroom 2
* Victor H. Engelhard, University of Virginia, USA

Andrew R. Ferguson, Sanofi Oncology, USA
Differential Homing Receptor Expression on T Cells Activated In Distinct Lymphoid Organs Resulting in T Cell Migration to Tumors

Michelle Li Wen Hong, Biomedical Sciences Institute, Singapore
The Role of the Immune System in the Control of Cancer in a Spontaneous Mouse Melanoma Model

Jennifer Landsberg, University of Bonn, Clinic for Dermatology, Germany
Primary Cutaneous Melanomas in HGFxCdk4R24C Mice Avoid Recognition and Destruction by the Cellular Immune System

Jacqueline D. Shields, Ecole Polytechnique Federale de Lausanne, Switzerland
Lymph Node Mimicry by Tumors Induces Immunological Tolerance in a Complement-Dependent Manner

Elizabeth D. Thompson, University of Virginia, USA
Tumors can Serve as a Primary Site of Naïve T Cell Activation

Roberta Faccio, Washington University, USA
Important Contribution of the Immune System in Regulating the Tumor/Bone Vicious Cycle Independent from Osteoclasts

14:30—16:30
Workshop 2: Tolerance and Regulatory Checkpoints

Ballroom 3
* Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA

Marieke F. Fransen, Leiden University Medical Center, Netherlands
Low Dose Anti-CD40 Activating Therapy in the Tumor-Draining Area is as Effective in Generating an Anti-Tumor CTL Response as a High Dose Systemic Therapy, with Decreased Toxicity

Lukas Kremmler, Netherlands Cancer Institute, Netherlands
The Role of PD-1 on MTOC Localization during the “Kiss of Death”

Amanda L. Sherwood, University of Western Australia, Australia
Dual Control of Anti-Tumor CD8 and Tumor-Promoting CD4 T Cells through the PD-1/PD-L1 Pathway

Jaikumar Duraiswamy, Emory University School of Medicine, USA
Programmed Death-1 Localization at the Immune Synapse is Different in Exhausted Versus Effector LCMV Specific T Cells

Andreas Bonertz, German Cancer Research Center, Germany
Regulatory T Cells Exhibit Highly Diverse Recognition Patterns of Tumor Antigens and Their Depletion Boosts the Reactivity of Tumor-Specific T Cells in Colorectal Carcinoma Patients

Joseph F. Grosso, Bristol-Myers Squibb, USA
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Tolerized CD8 T Cells

14:30—16:30
Workshop 3: gammadelta and NK Cells

Ballroom 1
* Jean-Jacques Fournié, INSERM-University U1037, France
Catch, Kiss and Kill: Gamma Delta T Cell-Based Cancer Immunotherapies

Massimo Massaia, Universita' degli Studi di Torino, Italy
Accumulation of Terminally Differentiated Effector Vgamma9/Vdelta2 T Cells in Patients with Chronic Lymphocytic Leukemia: a Novel Mechanism of Immunoediting Driven by the Mevalonate Pathway of Tumor Cells

Volker Kunzmann, Medizinische Klinik und Poliklinik II, Germany
gamma delta T Cell-Mediated Immunotherapy for Cancer: Current Reality and Future Options

Julie Dechanet-Merville, Université Bordeaux 2, France
Protection from Cancer After Kidney Transplantation is Correlated with Cytomegalovirus-Induced gamma delta T Cells

Hollie J. Jackson, Memorial Sloan Ketter Cancer Center, USA
Gene Modified Natural Killer Cells for Cancer Immunotherapy

Noureddine Himoudi, Institute of Child Health and Great Ormond Street Hospital, UK
The Bone Marrow Derived Interferon Producing Killer Dendritic Cells (IKDC) Subset of Cells Account for the Tumoricidal Activity of Unpulsed Dendritic Cells by Migrating into Tumors and Cross Presenting Antigens in vitro and in vivo

16:30—17:00
Coffee Available

Ballroom Lobby
17:00—19:00
Homing to Tumor Sites - You Can't Always Get Where You Want
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
Owen N. Witte, HHMI/University of California, Los Angeles, USA
Tracking Responses – It’s Nice Having a PET (Scanner)

Rachael A. Clark, Brigham and Women's Hospital, Harvard Medical School, USA
Short Talk: Imiquimod Enhances IFNgamma Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin

* Thomas Gajewski, University of Chicago, USA
T Cells and Tumors — An Avoidable Attraction

George Coukos, University Hospital of Lausanne - CHUV, Switzerland
“Seek (in the Soil) and You Shall Find”: Interrogation of the Tumor Microenvironment Reveals Critical Mechanisms Modulating Homing of T cells to Tumors

19:00—20:00
Social Hour with Lite Bites

Superior / Superior Lobby / Wasatch / Maybird
19:30—22:00
Poster Session 1

Superior / Superior Lobby / Wasatch / Maybird

TUESDAY, JANUARY 13

07:00—08:00
Breakfast

Golden Cliff / Eagles
08:00—11:00
Immunologic Restraint
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* James P. Allison, University of Texas MD Anderson Cancer Center, USA
Checkpoint Blockade in Tumor Immunotherapy: New Insights and Opportunities

Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Cell-Mediated Control of Immune Mediated Inflammation

Sergio A. Quezada, University College London, UK
Short Talk: CTLA-4 Blockade Prevents de Novo in vivo Generation of Foxp3+ and IL10+ Regulatory T Cells and Promotes Potent Tumor Rejection Upon Transfer of Tumor-Reactive CD4+ T Cells

Benoît J. Van den Eynde, University of Louvain, Belgium
Fighting Tumoral Immune Resistance

Richard A. Flavell, HHMI/Yale University School of Medicine, USA
Why TGF-beta May Not Be Good For You

09:20—09:40
Coffee Break

Ballroom Lobby
11:00
On Own for Lunch

11:00—13:00
Poster Setup

Superior / Superior Lobby / Wasatch / Maybird
13:00—22:00
Poster Viewing

Superior / Superior Lobby / Wasatch / Maybird
14:30—16:30
Workshop 4: Tumor Antigens

Ballroom 2
* Cornelis J. M. Melief, Leiden University Medical Center, Netherlands

Mirjam H.M. Heemskerk, Leiden University Medical Center, Netherlands
SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens

John J. Miles, QIMR Berghofer Medical Research Institute, Australia
The T Cell Receptor Repertoire to Epstein-Barr Virus

Inge Jedema, Leiden University Medical Center, Netherlands
High Avidity HLA-A2-Restricted CD8+ T Cells Against the Wilms Tumor Protein (WT1) Can Only be Isolated from HLA-A2 Negative Donors not Subjected to HLA-A2-Mediated Thymic Deletion

Karen Hastings, University of Arizona College of Medicine, Phoenix, USA
Lysosomal Thiol Reductase GILT is Important in Immune Recognition of Melanoma Antigen TRP1

Michel Kester, Leiden University Medical Center, Netherlands
A Proteomics Approach to Identification of Antigens for T Cell Mediated Immunotherapy

Peter A. Savage, University of Chicago, USA
Repertoire Selection of Tumor-Infiltrating T Cell Populations in a Mouse Model of Spontaneous Prostate Cancer

14:30—16:30
Workshop 5: Vaccines

Ballroom 3
* Jeffrey J. Molldrem, University of Texas MD Anderson Cancer Center, USA

Alice Yewdall, New York University, USA
Peptide-Loaded Dendritic Cell Vaccines Require Endogenous Antigen Presenting Cells for Maximal Naïve CD8+ T Cell Activation

Kimberly R. Jordan, University of Colorado Health Sciences Center, USA
Protective Mimotope Vaccines Elicit a Less Diverse Repertoire of T Cells that Produces IFN-gamma and have Higher Affinity for TAA

Lisa M. McEwen, University of Georgia, USA
Mechanistic Study of the DOTAP/E7 Therapeutic Vaccine

Hideho Okada, University of California, San Francisco, USA
Induction of Type-1 CTL Responses Against Novel Glioma-Associated Antigen -Derived Epitopes Epha2 (883-891) and IL-13Ralpha2 (345-353)

14:30—16:30
Workshop 6: Macrophages/Inflammation/Tumor Promotion

Ballroom 1
* Suzanne Ostrand-Rosenberg, University of Maryland, USA
Myeloid -Derived Suppressor Cells Inhibit T Cell Activation and Anti-Tumor Immunity by Sequestering Cystine and Cysteine

Marta Coscia, Università di Torino, Italy
Clinically Relevant Doses of Zoledronic Acid Efficiently Target Tumor Associated Macrophages and Cancer Microenvironment Prolonging Disease-Free and Overall Survival in a Transgenic Model of Human Breast Cancer

Matthew R. Porembka, Washington University in St. Louis, USA
Zoledronate Impairs Intratumoral Accumulation of Myeloid Derived Suppressor Cells Resulting in Smaller Tumors and Prolonged Survival

Brent H. Koehn, University of Minnesota, USA
Tolerogenic Programming of CD8 T Cells by B Cell APC

George C. Prendergast, Lankenau Institute for Medical Research, USA
IDO Pathway in Cancer and Immune Escape

Ainhoa Perez-Diez, NIAID, National Institutes of Health, USA
Tumor Specific CD4 Cells, but not CD8 Cells, Induce Phenotypic and Functional Changes on Tumor Associated Macrophages

16:30—17:00
Coffee Available

Ballroom Lobby
17:00—19:00
Innate Conditioning: 'Finis Origine Pendet'
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
Giorgio Trinchieri, NCI, National Institutes of Health, USA
Innate Resistance, Inflammation, and Cancer

* Kenneth M. Murphy, HHMI/Washington University School of Medicine, USA
Transcriptional Regulation of Dendritic Cell Subsets for Cross-Presentation and Tumor Rejection

Federica Sallusto, Università della Svizzera Italiana & ETH Zurich, Switzerland
Chemokine Receptors - Getting You Where You Need to Go

19:00—20:00
Social Hour with Lite Bites

Superior / Superior Lobby / Wasatch / Maybird
19:30—22:00
Poster Session 2

Superior / Superior Lobby / Wasatch / Maybird

WEDNESDAY, JANUARY 14

07:00—08:00
Breakfast

Golden Cliff / Eagles
08:00—11:00
Tumor Antigens: A Turn-On or a Turn-Off?
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
Bruce W. Robinson, University of Western Australia, Australia
Chemotherapy as a Strategy to Induce Antigen Presentation

Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
Combination Chemo-Immunotherapies: Looking for Synergy

Mark P. Chao, Stanford University, USA
Short Talk: CD47 Regulates a Mechanism of Immune Evasion in Acute Myeloid Leukemia Stem Cells

* Laurence Zitvogel, Institut Gustave Roussy, France
Novel Subsets of NK Cells and Regulation during Cancer Progression: Regulatory NK Cells and DC-like NK Cells

Jay A. Berzofsky, NCI, National Institutes of Health, USA
Role of NKT Cell Subsets in the Regulation of Anti-Tumor Immunity

09:20—09:40
Coffee Break

Ballroom Lobby
11:00
On Own for Lunch

11:00—13:00
Poster Setup

Superior / Superior Lobby / Wasatch / Maybird
13:00—22:00
Poster Viewing

Superior / Superior Lobby / Wasatch / Maybird
16:30—17:00
Coffee Available

Ballroom Lobby
17:00—19:00
Adoptive T Cell Therapy
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Philip D. Greenberg, University of Washington, USA
Building a T Cell Response Effective for Eradicating Tumors

Mark E. Dudley, Health & Human Services, National Institutes of Health, USA
Clinical Trials with Cell and Gene Therapy for Patients with Melanoma

Gert Riethmüller, University of Munich, Germany
Late Breaking Short Talk: The Promise of T Cell-Engaging BiTE Antibodies for Cancer Therapy

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Enhancing the Power of Tumor-Specific T Cells

19:00—20:00
Social Hour with Lite Bites

Superior / Superior Lobby / Wasatch / Maybird
19:30—22:00
Poster Session 3

Superior / Superior Lobby / Wasatch / Maybird

THURSDAY, JANUARY 15

07:00—08:00
Breakfast

Golden Cliff / Eagles
08:00—11:00
Vaccines to Treat Cancer
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
* Ralph M. Steinman, Rockefeller University, USA
Vaccination with Cancer Antigens Selectively Targeted to Dendritic Cells in situ

Lionel J. Apetoh, Centre Georges Francois Leclerc, France
Short Talk: Endogenous Danger Signals Ferried by Dying Tumor Cells to Dendritic Cells Dictate the Efficacy of Anticancer Chemotherapy and Radiotherapy

Nina Bhardwaj, Ichan School of Medicine at Mt Sinai, USA
Targeting Dendritic Cells to Enhance Anti-Cancer Immunity

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
Immune Responses Mediated By CTLA-4 Blockade

09:20—09:40
Coffee Break

Ballroom Lobby
11:00
On Own for Lunch

14:30—16:30
Workshop 7: Adoptive Therapy

Ballroom 2
* Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA

Salvatore Fiorenza, Diamantina Institute for Cancer, Immunology and Metabolic Medicine, Australia
Central Memory CD8 T Cells are More Potent than Effector Memory T Cells and Show Heightened Responses to a Local Inflammatory Stimulus

Michele L. Martin, University of Victoria, Canada
Identifying Tumor-Specific Determinants of T Cell Infiltration After Adoptive Immunotherapy

Tobias Seibel, German Cancer Research Center, Germany
Local Low Dose Irradiation Triggers Tumor Infiltration by Adoptively Transferred and Host T Lymphocytes and Enhances Immunotherapy in Mice

Ingunn M. Stromnes, Fred Hutchinson Cancer Research Center, USA
Targeting Cbl-b in Antigen-Specific CD8+ T Cells for Adoptive Immunotherapy of Progressive Leukemia in a Murine Model

Robbert M. Spaapen, Sanquin Research, Netherlands
Minor Histocompatibility Antigen Specific CD4+ T Cells for Adoptive Immunotherapy of Multiple Myeloma in Xenografted rag2-/-ãc-/- Mice

Eduardo Davila, Louisiana State University, USA
Overexpressing TLR2-MyD88 in Tumor-specific CD8 T cells Enhances Antitumor Activity

14:30—16:30
Workshop 8: Engineering Tumor Reactivity with TCRs/CARs

Ballroom 3
* Michael C. Jensen, University of Washington School of Medicine/Fred Hutchinson Cancer Research Center, USA

Zelig Eshhar, Weizmann Institute of Science, Israel
Redirected, Genetically Engineered T Cells for Adoptive Immunotherapy of Cancer

Gavin M. Bendle, Kite Pharma EU, Netherlands
TCR Gene Transfer-Induced GvHD Results in Lethal Pathology in Mice

Andy K. Sewell, Cardiff University, UK
Enhanced TCRs for Mobilizing Cellular Immunity for Cancer Therapy

Cor H. J. Lamers, Erasmus MC, Daniel den Hoed Cancer Center, Netherlands
Humoral and Cellular Immune Responses Towards the scFvG250 Transgene in the Rotterdam Retargeted T Cell Therapy Trial

Laura A. Johnson, Abramson Family Cancer Research Institute, University of Pennsylvania, USA
High Affinity T Cell Receptor Gene Therapy Breaks Tolerance and Elicits Autoimmunity and Cancer Regression

Reno Debets, Erasmus MC Cancer Institute, Netherlands
TCR Gene Transfer: MHC Class I and II-Restricted MAGE Epitopes as Melanoma-Specific Immune Targets

16:30—17:00
Coffee Available

Ballroom Lobby
17:00—18:40
HPV: Almost a Success Story, Lessons to be Learned
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
Ian Frazer, TRI, Australia
Preventing Cervical Cancer through Immunisation

* Cornelia L. Trimble, Johns Hopkins University School of Medicine, USA
At Your Cervix: Immune Therapies for HPV Disease

Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Induction of Objective Clinical Responses by Therapeutic Vaccination with Synthetic Long Peptides in Patients with High Grade HPV16-induced Premalignant Vulva Lesions

18:40—19:00
Concluding Remarks
Meeting has ended...abstracts no longer viewable online.

Ballroom 2-3
Ralph M. Steinman, Rockefeller University, USA
Gaining Traction on Translation

20:00—21:00
Social Hour with Lite Bites

Ballroom 1-2
20:00—23:00
Entertainment

Ballroom 1-2

FRIDAY, JANUARY 16

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Pfizer Global Research & Development

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676